Corrects Adjusted EPS in Key Details to -$0.23 from -$23

Overview

• Corteva Q3 revenue grows 13%, beating analyst expectations

• Company raises full-year 2025 guidance due to strong YTD performance

• Corteva plans separation into two independent companies by 2026

Outlook

• Corteva raises full-year 2025 net sales guidance to $17.7 bln-$17.9 bln

• Operating EBITDA for 2025 expected between $3.8 bln and $3.9 bln

• Corteva expects 2025 operating EPS of $3.25 to $3.35

Result Drivers

• CROP PROTECTION DEMAND - Double-digit volume growth in new products and biologicals drove Crop Protection results

• SEED DEMAND - Demand for newest hybrids and varieties, strong operational execution, and growth in out-licensing boosted Seed results

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the agricultural chemicals peer group is "buy"

• Wall Street's median 12-month price target for Corteva Inc is $79.00, about 21.4% above its November 3 closing price of $62.06

• The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release: ID:nPn5dcnqZa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)